🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase I Pipeline Programs

First-in-human and early clinical safety studies in Phase I.

Programs
4,713

Quick answer

NovaPharmaNews tracks 4,713 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.

Top sponsors

Page 18 of 99

  1. ALN-BCAT

    Alnylam Netherlands B.V.

    Advanced Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  2. ALN-F1202

    Regeneron UK Limited

    Healthy Volunteer

    phase 1 small molecule active

    1 trial

  3. ALN-HBV

    Alnylam Netherlands B.V.

    Hepatitis B

    phase 1 small molecule terminated

    1 trial

  4. ALN-HSD

    Alnylam Netherlands B.V.

    Nonalcoholic Steatohepatitis

    phase 1 small molecule terminated

    1 trial

  5. ALN-HTT02

    Alnylam Netherlands B.V.

    Huntington's Disease

    phase 1 small molecule active

    1 trial

  6. ALN-PCS02

    Alnylam Netherlands B.V.

    Elevated LDL-Cholesterol (LDL-C)

    phase 1 small molecule completed

    1 trial

  7. ALN-PCSSC

    Alnylam Netherlands B.V.

    Hypercholesterolemia

    phase 1 small molecule completed

    1 trial

  8. ALN-PNP

    Regeneron UK Limited

    Nonalcoholic Fatty Liver Disease (NAFLD)

    phase 1 small molecule completed

    1 trial

  9. ALN-SNCA

    Regeneron UK Limited

    Parkinsons Disease

    phase 1 small molecule active

    1 trial

  10. ALN-TTR01

    Alnylam Netherlands B.V.

    Transthyretin Mediated Amyloidosis (ATTR)

    phase 1 small molecule completed

    1 trial

  11. ALN-TTR02

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 1 small molecule completed

    1 trial

  12. ALN-TTRSC (revusiran)

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 1 small molecule completed

    1 trial

  13. ALN-TTRSC02

    Alnylam Netherlands B.V.

    Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)

    phase 1 small molecule completed

    1 trial

  14. ALN-TTRSC04

    Alnylam Netherlands B.V.

    Transthyretin-Mediated Amyloidosis

    phase 1 small molecule completed

    1 trial

  15. ALN-VSP02

    Alnylam Netherlands B.V.

    Solid Tumors

    phase 1 small molecule completed

    2 trials

  16. ALPN-101

    CNS Pharmaceuticals

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  17. ALS-002158

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 1 small molecule terminated

    1 trial

  18. ALS-002200

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 1 small molecule completed

    1 trial

  19. ALT-801

    Timmune Biotech

    Obesity

    phase 1 small molecule completed

    1 trial

  20. ALX2004

    ALX ONCOLOGY HOLDINGS INC

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 1 small molecule active

    1 trial

  21. AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

    Amgen

    Thoracic tumors with homozygous MTAP-deletion

    phase 1 other active

    1 trial

  22. AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion – Master Protocol

    Amgen

    Gastrointestinal tract, biliary tract, or pancreatic cancers with homozygous methylthioadenosine phosphorylase (MTAP)-deletion

    phase 1 other active

    1 trial

  23. AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors

    Amgen

    KRAS Altered Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  24. AMG 509

    BEONE MEDICINES AUS PTY LTD

    Prostate Cancer

    phase 1 small molecule active

    1 trial

  25. AMT-116

    Multitude Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  26. AMT-676

    Multitude Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  27. AMX0114

    Amylyx Pharmaceuticals EMEA B.V.

    ALS

    phase 1 small molecule active

    1 trial

  28. AN OPEN LABEL, TWO PERIODS, TWO SEQUENCES, CROSSOVER, RANDOMIZED MULTIPLE DOSE BIOEQUIVALENCE STUDY OF GUANFACINE 7 MG PROLONGED-RELEASE TABLETS (TEST FORMULATION) VS. EQUAL DOSE OF INTUNIV® PROLONGED-RELEASE TABLETS (REFERENCE FORMULATION) IN HEALTHY MALE VOLUNTEERS UNDER FASTING CONDITIONS

    NEURAXPHARM AUSTRALIA PTY LIMITED

    Study performed on healthy volunteers.

    phase 1 other active

    1 trial

  29. AN OPEN-LABEL, RANDOMIZED, SINGLE DOSE, TWO-STAGE CROSSOVER ADAPTIVE BIOEQUIVALENCE STUDY OF TRIAMCINOLONE ACETONIDE 40 MG/ML STERILE INJECTABLE SUSPENSION (Test product–Lisapharma S.p.A) VERSUS KENACORT® 40 MG/ML SUSPENSION (Reference product – Bristol Myers Squibb) AFTER INTRAMUSCULAR ADMINISTRATION TO HEALTHY VOLUNTEERS

    Lacuna Pharma Pty Ltd

    Intramuscular administration of triamcinolone acetonide Lisapharma (Injectable suspension of triamcinolone acetonide) is indicated for systemic corticosteroid therapy in morbid conditions such as allergic syndrome (to control severe or debilitating conditions not treatable in a conventional way), dermatoses, generalized rheumatoid arthritis and other connective tissue diseases.

    phase 1 other active

    1 trial

  30. AN2-502998

    AN2 Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  31. ANAWIDOW [antivenin latrodectus (black widow) equine immune F(ab)2] lyophilized powder for solution 10 mL

    Ultragenyx UK Limited

    Latrodectism

    phase 1 small molecule completed

    1 trial

  32. APG777

    Apogee Therapeutics

    Asthma

    phase 1 small molecule active

    1 trial

  33. APL-1202 and APL-1501 (Single ascending dose)

    Jian Li

    Bladder Cancer

    phase 1 small molecule active

    1 trial

  34. APOC-III-L-Rx

    IONIS PHARMACEUTICALS INC

    Elevated Triglycerides (TG)

    phase 1 small molecule completed

    1 trial

  35. APR-1051

    Aprea Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  36. APR-246

    Aprea Therapeutics

    Hematologic Neoplasms

    phase 1 small molecule completed

    1 trial

  37. APR-246

    Aprea Therapeutics

    Myeloid Malignancy

    phase 1 small molecule completed

    1 trial

  38. APR-548 + Azacitidine

    Aprea Therapeutics

    MDS

    phase 1 small molecule terminated

    1 trial

  39. APR002

    BRIGHT MINDS BIOSCIENCES INC.

    COVID-19

    phase 1 small molecule completed

    1 trial

  40. APTO-253

    Aptose Biosciences

    Acute Myelogenous Leukemia in Relapse

    phase 1 small molecule terminated

    1 trial

  41. APVO210

    Aptevo Therapeutics

    Psoriasis

    phase 1 mab terminated

    1 trial

  42. APVO436

    Aptevo Therapeutics

    AML

    phase 1 mab active

    2 trials

  43. APVO436

    Aptevo Therapeutics

    Acute Myeloid Leukemia (AML)

    phase 1 small molecule active

    1 trial

  44. APX005M treatment for recurrent or refractory primary malignant CNS tumor patients

    Pyxis Oncology

    Glioblastoma Multiforme

    phase 1 mab active

    1 trial

  45. ARAVA® 20 mg tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    1 trial

  46. ARC-520

    Arrowhead Pharmaceuticals Ireland Limited

    Healthy

    phase 1 small molecule completed

    2 trials

  47. ARC-521 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B

    phase 1 small molecule terminated

    1 trial

  48. ARCT-2138

    Arcturus Therapeutics Holdings

    Influenza, Human

    phase 1 mab completed

    1 trial

Frequently asked questions

How many Phase I pipeline programs are in the directory?

4,713 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.